Summit Therapeutics Plc Stock Buy Hold or Sell Recommendation

SMMT Stock  USD 20.69  2.20  11.90%   
Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding Summit Therapeutics PLC is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Summit Therapeutics PLC given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Summit Therapeutics PLC, the advice is generated through an automated system that utilizes algorithms and statistical models.
  
Check out Summit Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
Note, we conduct extensive research on individual companies such as Summit and provide practical buy, sell, or hold advice based on investors' constraints. Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Execute Summit Therapeutics Buy or Sell Advice

The Summit recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Summit Therapeutics PLC. Macroaxis does not own or have any residual interests in Summit Therapeutics PLC or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Summit Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Summit TherapeuticsBuy Summit Therapeutics
Cautious Hold

Market Performance

InsignificantDetails

Volatility

Not too volatileDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Below AverageDetails

Economic Sensitivity

Hyperactively responds to market trendsDetails

Investor Sentiment

InterestedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

PoorDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Summit Therapeutics PLC has a Mean Deviation of 3.84, Semi Deviation of 4.59, Standard Deviation of 5.2, Variance of 27.03, Downside Variance of 23.36 and Semi Variance of 21.04
Our trade recommendation module complements current analysts and expert consensus on Summit Therapeutics PLC. It analyzes the company potential to grow using all fundamental, technical, and market related data available at the time. To make sure Summit Therapeutics PLC is not overpriced, please validate all Summit Therapeutics fundamentals, including its book value per share, and the relationship between the net income and beta . Given that Summit Therapeutics PLC has a price to book of 39.29 X, we advise you to double-check Summit Therapeutics PLC market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.

Summit Therapeutics Trading Alerts and Improvement Suggestions

Summit Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (221.31 M) with profit before overhead, payroll, taxes, and interest of 705 K.
Summit Therapeutics PLC currently holds about 121.97 M in cash with (142.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61.
Summit Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 84.0% of the company outstanding shares are owned by corporate insiders
Latest headline from benzinga.com: This CoStar Group Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Friday

Summit Therapeutics Returns Distribution Density

The distribution of Summit Therapeutics' historical returns is an attempt to chart the uncertainty of Summit Therapeutics' future price movements. The chart of the probability distribution of Summit Therapeutics daily returns describes the distribution of returns around its average expected value. We use Summit Therapeutics PLC price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Summit Therapeutics returns is essential to provide solid investment advice for Summit Therapeutics.
Mean Return
0.31
Value At Risk
-7.91
Potential Upside
9.31
Standard Deviation
5.20
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Summit Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Summit Stock Institutional Investors

The Summit Therapeutics' institutional investors refer to entities that pool money to purchase Summit Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
Shares
Rock Springs Capital Management Lp2024-12-31
1.1 M
Goldman Sachs Group Inc2024-12-31
910 K
Northern Trust Corp2024-12-31
871.4 K
Candriam Luxembourg S.c.a.2024-12-31
842.6 K
Td Asset Management Inc2024-12-31
838 K
Pictet Asset Manangement Sa2024-09-30
691.4 K
Citadel Advisors Llc2024-09-30
650.8 K
Morgan Stanley - Brokerage Accounts2024-12-31
561 K
Twin Tree Management, Lp2024-12-31
495.8 K
Baker Bros Advisors Lp2024-12-31
24.4 M
Vanguard Group Inc2024-12-31
11.7 M
Note, although Summit Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Summit Therapeutics Cash Flow Accounts

202020212022202320242025 (projected)
Change In Cash2.6M5.4M576.8M(577.2M)33.8M35.5M
Free Cash Flow(48.5M)(72.9M)(42.2M)(76.9M)(142.2M)(135.1M)
Depreciation2.0M2.5M2.5M2.1M(2.5M)(2.4M)
Other Non Cash Items(385K)497K14.1M524.4M15.2M28.6M
Capital Expenditures421K306K624K128K139K132.1K
Net Income(52.7M)(88.6M)(78.8M)(614.9M)(221.3M)(210.2M)
End Period Cash Flow66.4M71.8M648.6M71.4M105.2M62.8M
Change To Netincome4.5M4.6M13.6M26.1M30.0M31.5M

Summit Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Summit Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Summit Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Summit stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
0.36
β
Beta against Dow Jones2.80
σ
Overall volatility
5.43
Ir
Information ratio 0.06

Summit Therapeutics Volatility Alert

Summit Therapeutics PLC exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Summit Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Summit Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Summit Therapeutics Fundamentals Vs Peers

Comparing Summit Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Summit Therapeutics' direct or indirect competition across all of the common fundamentals between Summit Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Summit Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Summit Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Summit Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Summit Therapeutics to competition
FundamentalsSummit TherapeuticsPeer Average
Return On Equity-0.95-0.31
Return On Asset-0.41-0.14
Current Valuation14.87 B16.62 B
Shares Outstanding737.68 M571.82 M
Shares Owned By Insiders84.36 %10.09 %
Shares Owned By Institutions12.92 %39.21 %
Number Of Shares Shorted21.45 M4.71 M
Price To Earning2.85 X28.72 X
Price To Book39.29 X9.51 X
Price To Sales753.90 X11.42 X
Gross Profit705 K27.38 B
EBITDA313 K3.9 B
Net Income(221.31 M)570.98 M
Cash And Equivalents121.97 M2.7 B
Cash Per Share0.61 X5.01 X
Total Debt7.22 M5.32 B
Debt To Equity0.03 %48.70 %
Current Ratio8.22 X2.16 X
Book Value Per Share0.53 X1.93 K
Cash Flow From Operations(142.11 M)971.22 M
Short Ratio9.26 X4.00 X
Earnings Per Share(0.31) X3.12 X
Target Price34.4
Number Of Employees15918.84 K
Beta-0.88-0.15
Market Capitalization15.26 B19.03 B
Total Asset435.56 M29.47 B
Retained Earnings(1.21 B)9.33 B
Working Capital382.02 M1.48 B
Current Asset20.86 M9.34 B
Current Liabilities3.21 M7.9 B
Net Asset435.56 M
Note: Acquisition by Xia Yu of 200000 shares of Summit Therapeutics at 2.64 subject to Rule 16b-3 [view details]

Summit Therapeutics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Summit . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Summit Therapeutics Buy or Sell Advice

When is the right time to buy or sell Summit Therapeutics PLC? Buying financial instruments such as Summit Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2024 2025 (projected)
Working Capital47.0M49.3M
Market Cap12.8B13.5B

Use Investing Ideas to Build Portfolios

In addition to having Summit Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Blockchain Thematic Idea Now

Blockchain
Blockchain Theme
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.